AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00761163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
Study NCT00761163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
Study NCT00761163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (Non-exercise)
Description: The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
Study NCT04023981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parafricta bootees
Description: Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
Study NCT01912807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose (D5NS)
Description: Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
Study NCT01912807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (Control)
Description: Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
Study NCT01608360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
Study NCT01608360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study NCT01554410 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: 45 Gy in 25 daily fractions (1.8 Gy per fraction)
Study NCT01554410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
Study NCT01554410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
Study NCT01262235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKM-080301
Description: Repeat dose IV infusion.
Study NCT03134664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
Study NCT03134664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
Study NCT02873845 — intervention group
Intervention type: OTHER
Intervention: Preliminary validation of the COBQoL questionnaire
Study NCT05282407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil 245mg
Description: 1 tablet q.d. for 48 weeks
Study NCT05282407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300mg
Description: 1 tablet q.d. for 48 weeks
Study NCT03784300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg PTI-125
Description: PTI-125 50 mg Oral Solution
Study NCT03784300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg PTI-125
Description: PTI-125 50 mg Oral Solution
Study NCT03784300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg PTI-125
Description: PTI-125 100 mg Oral Solution
Study NCT00877097 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Kliogest
Study NCT00877097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonefos
Study NCT04958512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao pill
Description: The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
Study NCT04958512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydergotoxine mesylate tablets
Description: The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
Study NCT04958512 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blank control group
Description: There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
Study NCT01459939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rose-hip powder capsules
Description: 5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
Study NCT01459939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
Study NCT00936429 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
Description: 3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
Study NCT00936429 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DEN1-80E
Description: 3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
Study NCT02496572 — intervention group
Intervention type: DRUG
Intervention: Short course MDR-TB treatment regimen
Description: Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration.
Study NCT00910247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: 800 to 2400 mg once daily (QD)
Study NCT03784924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI prostate
Description: MRI and laboratory biomarkers
Study NCT00456807 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT00456807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix TM
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study NCT03328182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New oral endotracheal tube holder
Description: The single arm study product is designed to hold a standard or subglottic ET tube.
Study NCT00003854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00003854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography
Study NCT00003854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Study NCT00003854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT00003854 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Study NCT00790257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encapsulated human islets in a Monolayer Cellular Device
Description: The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation.
Study NCT00622739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
Study NCT00622739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
Study NCT03643614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous regenerative cells of adipose tissue
Description: Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
Study NCT01921088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)
Description: Subjects are provided with RT-fMRI-NF.
Study NCT01921088 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)
Description: Subjects are provided with RT-fMRI-NF.
Study NCT01921088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory Training
Description: Subjects are provided with an ambulatory training.
Study NCT01921088 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Ambulatory Training
Description: Subjects are provided with an ambulatory training.
Study NCT01631656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: 15% gel on half the face, twice daily, 6 weeks
Study NCT01631656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:Yag laser
Description: Treatment with Nd:Yag laser , once at Week 2.
Study NCT01631656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:Yag laser
Description: Treatment with Nd:Yag laser , once at Week 2.
Study NCT03784300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 mg PTI-125
Description: PTI-125 100 mg Oral Solution
Study NCT03784300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg PTI-125
Description: PTI-125 200 mg Oral Solution
Study NCT03784300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 200 mg PTI-125
Description: PTI-125 200 mg Oral Solution
Study NCT00003456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT03849456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006
Description: Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
Study NCT01189227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
Study NCT01189227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Description: Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
Study NCT02936271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vasculera
Description: Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment.
Study NCT02936271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00366535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tabs b.i.d.
Study NCT00366535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: 4 tabs b.i.d.
Study NCT03763162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study NCT03763162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02086279 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GnRH analogue
Description: Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured.
Study NCT00490412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
Study NCT00490412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
Study NCT04103606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGBI: Positive Body Image (Mobile App)
Description: Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
Study NCT04103606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGBI: Positive Body Image (Mobile App)
Description: Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
Study NCT02048189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LEVEMIR
Study NCT02048189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: APIDRA
Study NCT03052543 — intervention group
Intervention type: DEVICE
Intervention: BIS™ Complete 2--Channel Monitor
Description: monitor depth of anesthesia
Study NCT04378452 — intervention group
Intervention type: BEHAVIORAL
Intervention: COM-COVID anonimous survey
Description: Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
Study NCT01730846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4mg/day
Description: 4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
Study NCT01730846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01730846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 8mg/day
Description: 8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
Study NCT02243982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [F18]-FDDNP
Description: radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
Study NCT01826838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 1.1 Primary Objective 1.1.1 To evaluate the maximum tolerated dose and dose limiting toxicities of dasatinib, up to a dose of 100mg/day, with concurrent standard radiation and hormone therapy for patients with intermediate and high risk prostate cancer.~1.2 Secondary Objective: 1.2.1 To determine the time to progression and overall survival for patients who are diagnosed with Intermediate and High Risk Prostate Cancer and were treated with dasatinib.
Study NCT03510923 — intervention group
Intervention type: OTHER
Intervention: Inspection and palpation of the appendix
Description: The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
Study NCT03510923 — intervention group
Intervention type: OTHER
Intervention: Inspection and palpation of the gallbladder
Description: The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
Study NCT02818790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Bodyguard + Precious App. Short onsite training session on how to use the system.
Study NCT02818790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
Study NCT01853722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCN01
Description: Three serial applications per periocular region.
Study NCT01853722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unisol
Description: Three serial applications per periocular region.